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NEW HORIZONS
Epigenetics in Liver Disease
Derek A. Mann
Epigenetics is a term that encompasses a variety of regulatory processes that are able to
crosstalk in order to influence gene expression and cell phenotype in response to envi-
ronmental cues. A deep understanding of epigenetics offers the potential for fresh
insights into the basis for complex chronic diseases and improved diagnostic and prog-
nostic tools. Moreover, as epigenetic modifications are highly plastic and responsive to
the environment, there is much excitement around the theme of epigenetic therapeutics,
including not only new drugs but also more informed patient advice on lifestyle choices
and their impact on pathology. This review briefly explains the molecular nature of the
individual regulatory process that constitute epigenetics, including DNA methylation,
histone modifications, chromatin remodeling, transcriptional control, and noncoding
RNAs. The ways in which these epigenetic mechanisms influence liver physiology and
disease will be considered in detail, particularly in the context of cancer, fibrosis, and
nonalcoholic steatohepatitis. The current limitations associated with epigenetic profiling
and therapeutics in liver disease are discussed, as is the intriguing possibility that
environmental-induced epigenetic changes may become stable and heritable. Conclusion:
The aim of the review is to inform hepatologists of the emerging key epigenetic ideas of
relevance to liver diseases that are highly likely to form a component of patient manage-
ment and care in the next decade. (HEPATOLOGY 2014;60:1418-1425)
A
n unanswered question in hepatology is why
only a significant minority of liver patients pro-
gress to severe symptomatic states, whereas the
majority remain relatively healthy. When we have the
answers to this question patient management will be
genuinely transformed, with anticipated advances in
disease prognosis, patient stratification, and therapeu-
tics. There are undoubtedly genetic influences which
become ever more apparent from genome-wide associ-
ation studies (GWAS). However, we still lack robust
genetic explanations for population variability in the
progression of liver disease to cirrhosis, hepatocellular
carcinoma (HCC), and organ failure. Deeper GWAS
may better illuminate the mechanistic basis for differ-
ential disease progression, as could the discovery of
rare genetic polymorphisms that map to fibrogenesis
and tumorigenesis. But additionally, there are many
epigenetic influences on cell phenotype and disease.
These signals operate literally above (“epi” meaning
“upon” in Greek) the DNA sequence. Epigenetic
mechanisms can operate at a genome-wide level to
influence gene expression and cell behavior, they are
highly dynamic, responsive to the cellular microenvir-
onment, and exhibit considerable molecular diversity
at the cellular, tissue, and organismal levels.
Brief Description of Epigenetics and Its
Constituent Regulatory Mechanisms
The consensus modern definition of an epigenetic trait
is “a stably inherited phenotype resulting from changes in a
chromosome without alterations in the DNA sequence.” By
“inherited” this definition holds true for transmission of
phenotype by both mitosis and meiosis. Most current
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reviews on epigenetics provide a narrow description usu-
ally focusing on three constituent regulatory systems;
DNA (CpG) methylation, histone posttranslational mod-
ifications, and microRNAs (miRNAs). In fact, the reader
should be aware of additional epigenetic influences such
as transcription factors, histone remodeling complexes,
and the entire gamut of noncoding RNAs, including the
long noncoding RNAs (lncRNAs) that have recently
emerged as regulators of chromatin structure and func-
tion (Fig. 1). Critically, there is substantial functional
crosstalk between these distinct epigenetic elements,
which combines to determine cell phenotype.
DNA Methylation
CpG methylation is a common DNA modification
that has a repressive influence on gene expression. It is
regulated by DNA methyltransferases (DNMT1,
DNMT3a, and DNMT3b) of which DNMT1 is a
maintenance methyltransferase necessary for faithful
copying of methyl-CpG marks to daughter DNA
strands during mitosis.1 Methylated CpGs repress tran-
scription by inhibiting the binding of transcription fac-
tors to DNA or by recruiting methyl-DNA binding
proteins (MBDs) that influence chromatin structure.1
The recent discovery of the Tet enzymes that catalyze
oxidation of methyl-CpG to generate hydroxymethyl-
CpG has revealed the dynamic nature of DNA meth-
ylation.2 The hydroxymethyl-CpG modification is not
only an intermediate step in the pathway to CpG
demethylation, it also has its own regulatory properties
and in contrast to methyl-CpG can stimulate gene
transcription. DNA methylation has a major influence
on phenotype; recent genome-scale DNA methylation
profiling in three distinct human populations (Cauca-
sian-, African-, Chinese-Americans) highlighted the
contribution of differences in DNA methylation
towards natural human variation.3
Histone Code
DNA is packaged by histones into chromatin, which
can take two forms: compacted transcriptionally inactive
heterochromatin or lightly packaged transcriptionally
permissive euchromatin. The basic structure of chroma-
tin (Fig. 1) has been famously depicted as “beads on a
string”; DNA being the string and the beads representing
nucleosomes consisting of 147bp of double-stranded
DNA (dsDNA) loosely wrapped around a core of eight
histone molecules (two copies each of H2A, H2B, H3,
and H4). The unstructured tail extensions of histones
can be modified by phosphorylation at serine residues,
methylation of arginine and by acetylation, methylation
(mono, di, and tri), ubiquitination, sumoylation, and
ADP-ribosylation at numerous lysine residues. Histone
acetylation relaxes histone-DNA interactions and are
associated with transcriptionally active chromatin. His-
tone lysine methylation plays a modulatory role in gene
regulation and, depending on the lysine residue
involved, will either suppress or promote transcription.4
Trimethylation of lysine 4 of histone 3 (H3K4me3) and
H3K36me2/3 are usually associated with euchromatin.
By contrast, H3K9me3 and H3K27me3 are associated
with heterochromatin and silenced genes. However, the
transcriptional activity of a gene is determined by the
cumulative influences of multiple histone modifications
(or a histone “code”). The histone code is actively
involved in control of cell phenotype, is highly dynamic,
and under the regulatory control of enzymes that either
add (“writers”) or remove (“erasers”) posttranslational
modifications. The code is then interpreted by mediator
proteins (“readers”) that affect histone-DNA interac-
tions and nucleosomal organization.4 Nucleosome struc-
ture can also be regulated by the exchange of core
histones with one or more histone variants.5 As an
example, exchange of H2A for H2A.Z is functionally
important in gene activation and silencing.
Fig. 1. An overview of epigenetic mechanisms influencing gene
expression. DNA is packed into histone octamers (or nucleosomes)
that are depicted as “beads” or “spools” on the DNA “string.” The
degree of compaction of nucleosomes at regulatory sequences is con-
trolled by modifications to the histone tails such as phosphorylation
(P), acetylation (Ac), and methylation (Me). Engagement of RNA poly-
merase II and associated transcriptional regulatory factors with chro-
matin at the gene promoter is reliant upon spacing and organization
of nucleosomal structure as dictated by chromatin remodeling proteins
(SWI/SNF). As transcription proceeds the ability of RNA polymerase II
to read through the gene and elongate the nascent transcript is
dependent on accessibility to downstream DNA, which is controlled by
additional histone signatures. As an example, the presence of the sig-
nature H3K27me3 enables the recruitment of polycomb group com-
plexes (PcG) which under the guidance of long noncoding RNAs
(lncRNAs) can bring about chromatin compaction at specific loci. Such
chromatin compaction in downstream regions of a gene will be inhibi-
tory to RNA polymerase II transcriptional elongation leading to stalled
or terminated transcription.
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Chromatin Remodeling and Compaction
The dense spacing and packaging of nucleosomes
needs to be remodeled to allow access to transcription
factors. This is carried out by the activities of adenosine
triphosphate (ATP)-dependent chromatin remodeling
complexes (e.g., mammalian SWI/SNF or BAF) that
alter nucleosome-DNA contacts, promote nucleosome
repositioning, or regulate the incorporation of variant
histones into the nucleosome.6 By contrast, silencing of
genes involves compaction of nucleosomes into dense
chromatin. The polycomb group (PcG) proteins repre-
sent a global gene silencing system that plays a critical
role in cell determination and fate. PcG proteins con-
tribute to two multiprotein complexes known as poly-
comb repressor complexes 1 and 2 (PRC1 and PRC2).
PRC2 and its constituent enzyme EZH2 stimulate
H3K27 trimethylation7; this epigenetic mark recruits
PRC1, a stimulator of chromatin compaction. Loss of
PcG function is implicated in cancers, in particular,
EZH2 is overexpressed in many human cancers where it
silences expression of tumor suppressor genes such as
the Ink4/Arf locus.7
Transcription Factors
Some transcription factors can exert a global influence
on gene expression and cell phenotype in the liver,
including members of the PPAR and CEBP transcrip-
tion factor families and regulators of the circadian clock
(e.g., CLOCK/BMAL) involved in control of hepatic
metabolism and bile synthesis. These proteins are
important in the epigenetic machinery since they are
directly wired into signaling events that are downstream
of extracellular receptors for environmental cues such as
microbes, nutrients, hormones, growth factors, and
xenobiotics. Moreover, a great many transcription fac-
tors engage in crosstalk with the chromatin regulatory
machinery through their direct interaction with coacti-
vators (e.g., histone acetyltransferases) or corepressors
(e.g., histone deacetylases) at target genes. Of relevance
to hepatologists, the bile acid sensor farnesoid X recep-
tor (FXR) regulates gene transcription in cooperation
with a number of coregulators such as SRC-1, SIRT1,
Brg-1, CARM1, PRMT1, and N-coR.8
Noncoding RNAs (ncRNAs)
Until recently, the majority of the noncoding
genome was thought to be “junk” DNA, but we are
now aware that it carries important regulatory infor-
mation transmitted by way of the ncRNAs. Most read-
ers will be familiar with miRNAs, which are short
(22 nucleotide) molecules that function in gene silenc-
ing and have already been manipulated for the design
of antivirals or as cancer drug targets.9,10 It is impor-
tant to also be aware of the long-noncoding RNAs
(lncRNAs), which are anticipated to be extremely
abundant and that are generated from a complex net-
work of overlapping sense and antisense transcripts
often including protein-coding loci.11,12 The lncRNAs
are implicated in almost every step of gene regulation
including transcription, splicing, and translation. Fur-
thermore, lncRNAs are able to recruit chromatin-
modifying complexes to specific genomic loci, thus
playing a fundamental epigenetic role. Not unexpect-
edly, relationships between lncRNAs and a variety of
human diseases including HCC are emerging.12
Epigenetics and Hepatocellular Carcinoma
DNA Methylation and HCC
Typical epigenetic lesions in liver cancer include
genome-scale changes in the DNA methylation land-
scape, loci-specific DNA hypermethylation, dysfunction
of histone-modifying enzymes, and abnormal expression
of ncRNAs. Cancer-related changes in DNA methylation
are attractive as biomarkers since they can be readily
detected and quantified from fixed tissues. As a conse-
quence, there are many published studies reporting DNA
methylation patterns specific to liver cancers of different
etiologies, including recent genome-wide studies. Com-
bined DNA methylation and transcriptome mapping in
human HCC identified 230 genes whose promoters were
hypomethylated and had elevated expression in HCC
(epigenetically induced), and 322 genes that were hyper-
methylated and underexpressed in tumors (epigenetically
repressed).13 Epigenetically induced genes were mapped
to pathways driving cellular differentiation and transfor-
mation, tumor growth, and metastasis. Repressed genes
mapped to apoptosis, cell adhesion, and cell cycle pro-
gression. A study of hepatitis B virus (HBV)-induced
HCC compared DNA methylation profiles between
tumor and adjacent tissue, this identified 1,640 hypome-
thylated and 684 hypermethylated CpG in the tumor.14
Using a similar approach, Song et al.15 reported that
62,692 loci displayed differential methylation between
HCC and surrounding tissue, of which a remarkable
61,058 were hypomethylated. In a more focused study,
tumor suppressor genes were identified that are hyperme-
thylated in the early stages of HCC.16 Eight genes
(HIC1, GSTP1, SOCS1, RASSF1, CDKN2A, APC,
RUNX3 and PRDM2) displayed significantly increased
methylation in early HCCs and were associated with
shorter-time-to-HCC occurrence.
Despite the excitement surrounding genome-wide
DNA methylation studies, there are a number of cav-
eats to be considered that urge caution regarding the
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clinical and biological significance of the emerging
datasets. Perhaps of most importance is that tumors
have high cellular heterogeneity, as such observed dif-
ferences in DNA methylation patterns may simply
reflect differences in numbers of tumor to normal cells
rather than identifying epigenetic signatures relevant to
cancer biology. For DNA methylation profiling to
deliver definitively relevant clinical data, it will be nec-
essary to carry out quantitative analysis on small num-
bers of histologically verified tumor cells captured
from tissue by a technique such as laser dissection
microscopy or high-speed cell sorting. A further caveat
is that we must not assume a simple relationship
between changes in DNA methylation and altered
gene expression, even where this is indicated by over-
laid transcriptome data. A direct functional correlation
would require in vivo experimental manipulation of
DNA methylation in a site-directed manner and dem-
onstration of an associated change in the rate of gene
transcription.
Viruses as Drivers of Epigenetic Changes
Underlying HCC
Cancers of viral origin can provide insights into rela-
tionships between epigenetics and tumor biology. The
oncogenic HBx protein of HBV induces the expression
of DNMT1 and recruits DNMT1, 3a, and 3b to stimu-
late hypermethylation of IGFBP-3 and p16INK.17 One
mechanism by which HBx has been proposed to induce
DNMT1 is by down-regulating microRNA miR-152,
which directly targets the DNMT1 transcript.18 Overex-
pression of miR-152 results in global DNA hypomethy-
lation, whereas inhibition of miR-152 caused global
hypermethylation and increased DNA methylation at
the GSTP1 and CDH1 tumor suppressor genes. HCV
has also been shown to stimulate alterations in DNA
methylation; for example, the Gadd45b promoter is
hypermethylated in HCV transgenic mouse liver and in
cells infected with the JFH1 strain of HCV.19 Gadd45b
is expressed at reduced levels in HCV-infected patients
and in tumor tissue; this is functionally significant given
the role of Gadd45b in the control of cell cycle, growth
arrest, and DNA repair. Studies in HBV- and HCV-
induced HCC have identified common functional
mutations in the SWI/SNF-like ATP-dependent chro-
matin remodeling enzymes ARID1A and ARID2.20-22
Exome sequencing in an HCC tumor and adjacent non-
tumor tissue of HBV/HCV origin discovered missense
mutations in genes encoding the H3K4 methyltransfer-
ases MLL, MLL2, MLL3, and MLL4.23 These enzymes
are important for remodeling chromatin into a tran-
scriptionally active state. MLL4 is of particular interest,
being a recurrent hotspot for HBV integration and con-
sidering its role as a regulator of p53 target genes.23
The PRC2 methyltransferase EZH2 and its struc-
tural partners EED, SUZ12, and RBP7 are expressed
at elevated levels in human HCC and contribute to
tumorigenesis by silencing multiple miRNAs.24 The
PRC2-regulated miR-125b is a transcriptional core-
pressor of the H3K9 methyltransferase SUV39H (Fig.
2), which regulates heterochromatin formation.25
SUV39H is overexpressed in human HCC and when
knocked-down in HCC cell lines inhibits proliferation
and migration. SUV39H is a repressor of miR-122,
which is best known for its ability to stimulate transla-
tion of HCV RNA (Fig. 2). However, miR-122 is
decreased in HBV infection and when genetically
deleted in mice results in spontaneous hepatosteatosis,
inflammation, fibrosis, and HCC.26,27 HBx represses
miR-122 by recruiting peroxisome proliferator-
activated receptor gamma (PPARc) and its associated
SUV39H-containing corepressor complex to the miR-
122 promoter.28 Hence, altered expression or mutation
of histone methyltransferase genes in HCC disrupts
multiple regulatory networks, including a large num-
ber of miRNAs involved in posttranscriptional control.
Fig. 2. An example of complex epigenetic crosstalk and its impact
on liver physiology and disease. The histone methyltransferase
SUV39H plays a central regulatory role in liver physiology; on the one
hand, negatively regulating the expression of the microRNA miR-122,
which orchestrates the epigenetic control of gene networks involved in
lipid metabolism and HCC. In addition, miR-122 is critical in the life
cycle of HCV and is considered a therapeutic target. On the other
hand, SUV39H regulates histone modifications at genes encoding reg-
ulators of cell proliferation and migration, its overexpression is associ-
ated with HCC. Expression of SUV39H is posttranscriptionally
regulated by miR-125, which in turn is transcriptionally under the
influence of the polycomb group complex PRC2 and its H3K27 meth-
yltransferase EZH2.
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Drugs that modulate the activity of one or more of
these epigenetic enzymes may be of considerable thera-
peutic potential.
A number of miRNAs are of mechanistic relevance in
HCC and are described in detail elsewhere.14 LncRNAs
have so far received considerably less attention; however,
several are emerging as potentially important in HCC.
Highly Up-regulated in Liver Cancer (HULC) is a 500
nucleotide lncRNA which was discovered from a screen
of noncoding RNAs expressed in HCC. HULC is
expressed in normal human hepatocytes but is strongly
induced in HCC tissue.29 Elevated HULC expression is
also a feature of HBV infection30 and is found in liver
metastatic tissue of colorectal cancer origin. HULC regu-
lates HCC proliferation and expression of a number of
HCC-associated genes and is detected in the sera of
HCC patients, the latter raising potential for biomarker
development. HOTAIR is expressed in HCC and is asso-
ciated with a higher risk of tumor recurrence following
therapeutic transplantation.31 Depletion of HOTAIR
inhibits tumor cell proliferation, stimulates apoptosis,
and generates significant antitumor effects in vivo.32
MALAT1 is a very large (8,000 nt) nuclear lncRNA
expressed in HCC and is associated with high risk of
posttransplant recurrence.33 Knockdown of MALAT1 in
HCC cell lines has similar behavioral effects to those
described for depletion of HOTAIR. Future work with
lncRNAs is greatly anticipated and expected to lead to
exciting new insights into hepatic gene regulation.
Epigenetics and Liver Fibrosis
Hepatic stellate cell (HSC) transdifferentiation to a
profibrogenic myofibroblastic phenotype is a pivotal
event in fibrogenesis. Transdifferentiation requires
global epigenetic remodeling to bring about the sup-
pression of adipogenic differentiation factors, de novo
expression of regulators of the myofibroblast pheno-
type, and cell cycle entry. According to Waddingtons
famous epigenetic landscape model,34 reversion or con-
version of a differentiated state is energetically costly for
the cell and this ensures the stability of cell phenotype
and tissue organization. Hence, the HSC may need to
overcome energy-dependent epigenetic barriers to adopt
the myofibroblast phenotype. In this respect, it is note-
worthy that autophagy, a mechanism by which the cell
recycles its intracellular components to generate energy,
is critical for HSC activation.35 Small molecular epige-
netic inhibitors such as the DNMT1 inhibitor
5-azadeoxycytidine (5-AzadC) and the EZH2 inhibitor
3-deazaneplanocin A (dZNep) potently inhibit HSC
activation in vitro and in vivo.36,37 Studies in our labo-
ratory have described an epigenetic relay pathway that
must be activated in order to drive HSC transdifferen-
tiation.37 Mice lacking MeCP2 are protected from liver
fibrosis and mecp2-deficient HSC display multiple
defects in their fibrogenic phenotype including reduced
expression of collagen I, TIMP-1, and a-SMA. MeCP2
may be a generic core-regulator of tissue fibrosis since
mecp2-deleted mice are also protected from pulmonary
fibrosis.38 MeCP2 operates two concurrent mechanisms
to ensure epigenetic silencing of PPARc and HSC
transdifferentiation. MeCP2 directly binds to methyl-
CpG-rich regulatory regions in the PPARc promoter
and recruits H3K9me3-modifying enzymes that sup-
press transcription initiation. MeCP2 is also required
for expression of EZH2 and H3K27me3 modifications
in the downstream coding region of the gene that
impede transcriptional elongation. These two mecha-
nisms help explain the ability of 5AzadC and dZNep to
inhibit HSC transdifferentiation. More recently, our
laboratory described how MeCP2 can promote tran-
scription of multiple profibrogenic genes through its
control of the expression of the H3K4/H3K36 methyl-
transferase ASH1.39
Changes in DNA methylation during HSC activa-
tion have been reported at specific loci such as the
PTEN tumor suppressor and Patched 1 (PTCH1)
genes; in both cases the genes become hypermethylated
and this corresponds with diminished expression in the
myofibroblast.40 To date, we lack genome-wide studies
of changes in DNA methylation during HSC activa-
tion. However, a landmark study recently published
from the Diehl laboratory interrogated 69,247 differen-
tially methylated CpG sites in liver biopsy material
from nonalcoholic fatty liver disease (NAFLD) patients
stratified into advanced (F3-4) versus mild (F0-1) dis-
ease.41 76% of the differentially modified CpG sites
became hypomethylated in advanced disease, while
24% underwent hypermethylation. The mechanistic
basis for these NAFLD-associated changes in DNA
methylation was not investigated. The DNA methyl-
ome data were overlaid with transcriptomics data from
the same biopsies; this led to the discovery of several
key fibrogenic genes that were both hypomethylated
and overexpressed in advanced NAFLD. However,
when using whole tissue for DNA methylome analysis
there is a risk that observed differences may simply be
reflecting cellular and/or architectural changes in the
tissue rather than identifying molecular changes that
are driving fibrogenesis. There is also no proof that the
alterations in DNA methylation are directly responsible
for the observed differences in gene expression; the two
may simply be coincidental.
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It is highly likely that noncoding RNAs of all sizes
and activities will play fundamental functions in the
determination of HSC phenotype and liver fibrosis.
Numerous miRNAs regulating proliferation, apoptosis,
TGFb1 signaling, and collagen expression have been
described as regulators of HSC phenotype and fibrosis
progression.42 We await investigations into the func-
tions of lncRNA species.
Epigenetics and Nonalcoholic
Steatohepatitis (NASH)
The associations between nutrition, epigenetics, and
metabolic disease are firmly established. The phenotype
of the Agouti mouse, which includes obesity and pre-
disposition to cancer, is prevented by supplementation
of the maternal diet with methyl donors.43 Diets
depleted of methyl donors promote DNA hypomethy-
lation and the development of steatosis in rodents. By
contrast, supplementation of high-calorie diets with
methyl donors prevents NAFLD, suggesting that epige-
netic changes that alter hepatic fat metabolism may be
related to dynamic alterations in DNA methyla-
tion.44,45 There is a close association between lipid
metabolism and circadian rhythm, the latter being con-
trolled by the CLOCK machinery. The CLOCK-
BMAL1 circadian transcription factors regulate hun-
dreds of genes including the PPARs; hence, metabolic
genes regulated by PPARs are rhythmically expressed.46
Mice lacking the expression of Clock are hyperphagic,
obese, and develop NASH.47 The deacetylase SIRT1
forms a chromatin complex with CLOCK-BMAL1 and
its activity is regulated in a circadian manner. This
CLOCK-SIRT complex determines the degree of his-
tone acetylation and amplitude of transcription for cir-
cadian and metabolic genes. Moderate overexpression
of Sirt1 in mice protects from high-fat-diet-induced
metabolic disease.48 These data are of relevance when
considering epidemiological data in humans with dis-
turbed circadian rhythms such as shift workers who
have a high risk of metabolic disorders.49 However,
clinical studies investigating epigenetic reprogramming
in NASH are only just beginning to emerge. Ahrens
et al.50 carried out DNA methylation and transcrip-
tome analysis on liver biopsies from lean controls,
healthy obese, and NASH patients. Analysis of 45,000
CpG sites revealed 467 dinucleotides where methyla-
tion deviated from lean controls. By overlay with tran-
scriptome data, eight genes were identified (GALNTL4,
ACLY, IGFBP2, PLCG1, PRKCE, IGF1, IP6K3 and
PC) that displayed obesity-related alterations in expres-
sion correlating in an inverse manner with altered CpG
methylation. Noteworthy is that all of these genes are
regulators of metabolism and candidates for NAFLD
disease drivers. As part of the same study, a similar
analysis was also carried out with paired liver biopsies
obtained 5-9 months following bariatric surgery. The
gene encoding protein-tyrosine phosphatase epsilon
(PTPRE), a negative regulator of insulin signaling,
became hypermethylated and transcriptionally down-
regulated with weight loss. This finding provides an
interesting mechanistic link between weight loss and
control of hepatic insulin sensitivity.
Progression to steatohepatitis is a critical step in the
continuum of NAFLD towards fibrotic disease and/or
HCC. A plausible hypothesis for progression of benign
steatosis to steatohepatitis is the perturbed regulation
of inflammatory cytokines (e.g., interleukin [IL]-6, IL-
1, and tumor necrosis factor alpha [TNFa]). Hepato-
cytes cultured with free fatty acids overexpress the
ATP-dependent chromatin remodeling proteins Brg1
and Brm, which upon recruitment to proinflammatory
genes stabilize nuclear factor kappa B (NF-jB) binding
and help remodel chromatin.51 Impressively, experi-
mental depletion of Brg1 into MCD-fed mice sup-
pressed steatosis, inflammation, and fibrosis, indicating
a pivotal role for Brg/Brm chromatin remodeling pro-
teins in the progression of NAFLD.
Investigations of noncoding RNAs in NASH have so
far been limited to miRNAs. On the order of 100 miR-
NAs are reported to be differentially expressed in NASH
and these have vast functional diversity, including control
of lipid and glucose metabolism.52 Noteworthy is miR-
122, which plays important regulatory functions in lipid
and cholesterol metabolism and is closely linked to the
circadian clock system. mIR-122 is abundantly expressed
in healthy liver but down-regulated in NASH, and in
experimental studies in mice has been functionally impli-
cated in NAFLD pathology.53
Epigenetics and Liver Disease Imprinting
The concept that environmental cues may induce
stable adaptive traits that can be passed between gen-
erations and influence phenotype has its theoretical
roots in so-called “Lamarckian” inheritance. Until
recently, there was limited convincing experimental
evidence for epigenetic transgenerational effects in
mammals and most studies were of maternal origin,
where it can be argued that contributory in utero
events confound data interpretation. By contrast,
paternal effects are more attributable to true epigenetic
inheritance, as fathers usually only contribute sperm
to offspring. Of relevance, there are intriguing recent
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reports for paternally transmitted heritable epigenetic
adaptations that impact on liver function. Male inbred
mice fed a low-protein diet gave rise to offspring that
exhibited elevated hepatic expression of genes regulat-
ing lipid and cholesterol metabolism.54 Liver fibrosis
in male outbred rats triggers the multigenerational
transmission of changes in the expression of genes reg-
ulating hepatic stellate cell activation, with the pheno-
typic consequence being suppression of liver fibrosis.55
Interestingly, in both of these studies DNA methyla-
tion and gene expression for PPARa and PPARc were
altered; this may indicate that these nuclear hormone
receptors provide an epigenetic hub for integrating
ancestral environmental information. Evidence for
Lamarckian-like inheritance is rare in humans,
although intergenerational inheritance of metabolic
disorders following the 1944-1945 Dutch famine does
provide a striking example. As reported by Veenendaal
et al.,56 body mass index (BMI) and weight are
increased in F2 (grandchildren) of males exposed to in
utero famine, suggesting that epigenetic adaptations to
dietary factors may be stable and transmissible across
multiple generations. Whether such ancestral epige-
netic imprinting contributes to population variability
in liver diseases remains to be determined.
Summary and Future Prospects
Genetic and epigenetic variants combine to influ-
ence observed differences in disease susceptibility and
variable disease progression. Based on the experience
with GWAS, it is inevitable that epigenome-wide asso-
ciation studies (EWAS) in liver diseases will be under-
taken. However, conducting meaningful EWAS will be
challenging, as epigenetic signatures are highly plastic,
display differences between cells within a tissue, and
are modified by aging and multiple environmental fac-
tors. But if carefully conducted, EWAS combined with
GWAS offers the rewards of unparalleled mechanistic
insights into disease pathology, improved patient strati-
fication, and new prognostic tools. Unlike genetic driv-
ers of disease, unhealthy epigenetic modifications may
be modified, thus offering the prospect of epigenetic
therapies. There are already ongoing clinical trials with
HDAC inhibitors in cancer, the miR-122 inhibitor
miravirsen in chronic HCV, and first-into-man trials
with a mimetic of miR-34, a powerful tumor suppres-
sor.57,58 But again, enthusiasm must be tempered with
what are significant hurdles to be overcome, not the
least in finding drugs with sufficient specificity for a
given epigenetic modifier to ensure efficacy and pre-
vent clinical toxicities. Notably, very few HDAC
inhibitors have completed phase II testing due to
adverse side effects including fatigue, constipation,
diarrhea, and dehydration.59 Ideally, combined GWAS
and EWAS information will arm clinicians and dieti-
cians with the tools to design evidence-based lifestyle
modification strategies tailored to prevent liver disease
developing in at-risk individuals and from passing on
unhealthy epigenetic traits to future generations.
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